

J. DAVID ALFORD, D.D.S.  
President



BILLY W. TARPLEY  
Executive Director

6200 02 22 10 29

August 28, 2002

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane  
Room 1061  
Rockville, MD 20057.

*Re: Support for FDA proposal on dental amalgam*

Dear Sirs:

The Arkansas State Dental Association wishes to submit the following comments regarding the Food and Drug Administration's proposed rule on dental amalgam products and draft guidance document entitled, "Special Control Guidance Document on Encapsulated Amalgam, Amalgam Alloy, and Dental Mercury Labeling."

1. The ASDA supports the comments submitted recently by the American Dental Association ("ADA") in their entirety.
2. The ASDA agrees with and supports the FDA's proposal to:
  - Issue a separate classification regulation for encapsulated amalgam alloy and dental mercury as a class II device with special controls;
  - Amend the existing classification for amalgam alloy, a class II preamendments device, by adding special controls; and
  - Reclassify from class I (general controls) to class II with special controls, dental mercury.
3. As noted in the comments from the ADA, state laws regarding disclosure requirements for products that contain dental mercury or calling for the abolishment of dental amalgam products are directly at odds and incompatible with the federal requirements set forth by the FDA.

The FDA and other reputable scientific agencies have spent years studying the safety of dental amalgam. The conclusion has consistently been that there exists no meritorious scientific evidence to indicate that the use of dental amalgam causes any adverse health effects, except in rare instances where a person has an allergy to one component of the amalgam alloy. A uniform class II classification with special controls is appropriate to provide a reasonable assurance of safety of dental amalgam products for all dental patients and dental providers.

Thank you for the opportunity to provide comments on this matter.

Sincerely,


  
Billy Tarpley  
Executive Director

01N-0067

C48



2501 Crestwood Dr., Suite 205  
North Little Rock, AR 72116-1016



Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane Room 1061  
Rockville MD 20057

20837+0001

